INC Research, SAS Collaborate to Improve Clinical Trials Outcomes
INC Research and SAS are working together to improve clinical development risk management and achieve targeted product profiles through analytics. Collaborating with SAS, INC Research aims to offer biopharmaceutical customers an integrated suite of tools to increase decision-making speed, efficiency, and flexibility. The ultimate goal is to improve a customer’s ability to manage risk, control investment, and maximize ROI in clinical development.
“In an environment of growing trial complexity and shrinking R&D budgets, our biopharmaceutical customers demand innovative solutions and enhanced efficiencies in drug development,” said James Ogle, INC Research Chief Executive Officer. “By joining forces with SAS and its advanced analytics platform, INC Research aims to help customers better predict commercially successful outcomes earlier in the process to maximize development efforts.”
SAS’ advanced analytics platform will boost INC Research’s ability to optimize clinical trial designs and proactively manage operations. By gaining access to SAS software through a hosted delivery model, INC Research hopes customers will achieve more rapid and informed decisions, faster time to market, and improved cash flow.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
